


Al-Quds University

Deanship of Graduate Studies



**Treatment satisfaction, its relation with beliefs about
medicine, quality of life and adherence among diabetic
patients.**

Heba Bassam Said Awadallah

M.Sc. Thesis.

Jerusalem, Palestine.

1441/2019

**Treatment satisfaction, its relation with beliefs about
medicine, quality of life and adherence among diabetic
patients.**

Prepared By:

Heba Bassam Said Awadallah

B.Sc. Pharmacy, Al-Quds University, Palestine

Supervisor: Dr. Maher Khdour.

**This thesis is submitted in partial fulfillment of requirements for
the degree of Master of Pharmaceutical Sciences in the Faculty of
Pharmacy- Al-Quds University.**

1441/2019

Al-Quds University
Deanship of Graduate studies
Pharmaceutical Science Program



Thesis Approval

Treatment satisfaction, its relation with beliefs about medicine, quality of life
and adherence among diabetic patients

Prepared by: Heba Bassam Said Awadallah.

Registration No: 21310168

Supervisor: Dr. Maher Khmour

Master thesis Submitted and accepted, Date: 14/12/2019

The names and signatures of the examining committee members are as
follows:

1-Head of committee: Dr. Maher Khmour signature:*Maher*.....

2-Internal examiner: Dr. Hussein Hallak signature:*H. Hallak*.....

3-External Examiner: Dr. Rowa Al Ramahi signature:*Rowa*.....

Jerusalem – Palestine

1441/ 2019

Dedication:

I dedicate my master thesis to My Deceased father who gave me a better life and my lovely Mother, who gave me love encouragement and endless support all the way.

Declaration

I certify that this thesis submitted for the degree of Master, is the result of my own research, except where otherwise acknowledged, and that this study (or any part of the same) has not been submitted for a higher degree to any other university or institution.

Signed: 

Heba Bassam Said Awadallah

Date: 14/12/2019

ACKNOWLEDGEMENT

I would like thank all who helped me in the completion of my Mater thesis. First, I give thanks to God.

I would like to convey my thanks to my advisor Dr. Maher Khmour , for his assistance and guidance, his door was always open when I was in trouble or asked about my survey or writing. He consistently steered me in the right direction whenever he thought I needed it.

I would like to thank all diabetic patients who took apart in the study and I hope this study will contribute to the improvement of DM management in Palestine.

I also would like to thank my family who motivated me and helped me throughout my research. This thesis is sincerely devoted to my mother whose prayers protect and support me all the time.

Abstract.

Objectives and Background: Diabetes mellitus (DM) is a progressive disease resulted from inadequate insulin secretion, insulin sensitivity problems, or both resulting in increased blood glucose that diabetes distinguish with it. Insulin's function as an anabolic hormone associated with carbohydrate, lipid and protein metabolic disorders .The aim of this study was to assess medication adherence and its association with glycemic control, treatment satisfaction, patients' beliefs about medicines and Health related Quality of life.

Methodology: Three hundred and eighty patients from primary clinic in Ramallah were recruited in the current cross sectional study. Medication adherence were measured using Morisky four-item Medication Adherence Scale (MMAS-4). Last value of HbA1c test was used to measures glycemic control. Treatment Satisfaction Questionnaire for Medication (TSQM 1.4) was used to assess treatment satisfaction. Beliefs about medicines was measured using Beliefs about Medicines Questionnaire (BMQ). Health related quality of life was measured by using EQ-5D (EuroQol 5 Dimensions Patients). Medical records were used to collect the patients' demographic and clinical information.

Results: The result of our study indicated that 220 (57.9%) of the diabetic patients were classified as high adherent to their medications and 160 (42.1%) were classified as low adherent according to MMAS-4. 174, (45.7%) of patients had good glycemic control ($HbA1c \leq 7$), whereas 206, (54.2%) had poor glycemic control ($HbA1c > 7$). The mean \pm SD of satisfaction domains of adherent patients were 78.81 ± 25.8 and for non-adherent were 68.89 ± 36.4 for effectiveness, while mean \pm SD of adherence were 41.85 ± 40.8 and non-adherence 44.86 ± 40.2 . For side effects satisfaction domains, mean \pm SD of adherence were 57.76 ± 38.2 and non-adherence 63.26 ± 37.3 for convenience and the mean \pm SD of global satisfaction of adherence were 68.66 ± 34.2 and non-adherence 61.31 ± 36.4 . There was a positive significant correlation between effectiveness and adherence level ($P = 0.04$). Mean of Specific necessity scale 17.9 (SD=6.43). This

represent that the patients had a strong belief in their need to their medications to maintain their health. Scores for patient's concerns of their prescribed medication (Specific-Concerns scale), with a mean of 13.81 (SD=6.05). This represents that the patients had medium concerns about the side effects of their medications. Glycemic control had significant correlation with global Satisfaction domain ($p=0.01$). The classification of patient's responses to EQ-5D Domains. Pain/Discomfort were the most influenced dimensions (173 patients reported problems, 36.1%), Anxiety and depression (128 patients reported problems, 33.7%) and the mobility (115 patients reported problems, 30.3%). Treatment satisfaction had significant association with anxiety domain ($p=0.031$).

Conclusion: More than half of the patients in this study were classified as high adherent to their medications and believed strongly that their medicines had to be used. Controlled glycemic level was significantly associated with treatment satisfaction. Many patients were satisfied with their treatment; more satisfied patients were more adherent to the medication and had better quality of life.

List of Abbreviations

DM	Diabetes Mellitus
BMI	Body Mass Index
BMQ	Beliefs about Medicines Questionnaire
FPG	Fasting Plasma Glucose
GDM	Gestational Diabetes Mellitus
HbA1c	Glycosylated Hemoglobin
MMAS-4	4-item Morisky Medication Adherence Scale
OGTT	Oral Glucose Tolerance Test
PPAR- γ	Peroxisome Proliferation Activated Receptor-gamma
T1DM	Type 1 Diabetes Mellitus
T2DM	Type 2 Diabetes Mellitus
TSQM 1.4	Treatment Satisfaction Questionnaire for Medication
GDM	Gestational Diabetes Mellitus
GLP-1–receptor agonists	Glucagon-like Peptide-1receptor Agonists
DPP-4	Dipeptidyl peptidase 4
GLP-1	glucagon-like polypeptide-1
GIP	glucose-dependent insulintropic polypeptide
IAPP	islet amyloid polypeptide
HRQoL	Health related quality of life

WHO	World Health Organization
ADDQOL	Audit of Diabetes-Dependent Quality of Life
WHOQOL-BREF	World Health Organization Quality of Life – Brief
EUROQOL	The European Quality of Life
UNRWA	United Nations Relief and Works Agency
NGO	nongovernmental organizations
UUTH	University of Uyo Teaching Hospital
UCTH	University of Calabar Teaching Hospital
HFS-II	Hypoglycemia Fear Survey
MDQoL	modified diabetes quality of life
EFF	Effectiveness
SE	Side Effects
QoL	Quality of life

Contents

Declaration	i
ACKNOWLEDGEMENT.....	ii
Abstract.....	iii
List of Abbreviations	v
List of Tables:.....	x
List of Figures:.....	xi
List of Appendixes:.....	xii
Chapter One	1
1. Introduction.....	1
1.1Background.....	1
1.1.1Diabetes definition and classification.....	1
1.1.2 Epidemiology of DM.....	1
1.1.3 Pathophysiology.....	2
1.1.4 Diagnosis.....	3
1.1.5 Complications of Diabetes Mellitus.....	3
1.1.6 Types of DM.....	4
1.1.7 Management of DM:.....	4
1.1.8 Diet:	4
1.1.9 Physical activity:.....	5
1.1.10 Treatment of Diabetes Mellitus:	5
1.1.11 Treatment satisfaction:.....	9
1.1.12 Medication adherence:	10
Other Classifications:	11
1.1.13 Patient’s believes about medicine:.....	12
1.1.14 Quality of life (QoL):.....	12

1.2 Problem statement:	13
1.3 Significance of the Study.	14
1.4 Aim of the study:.....	15
1.4.1 Objectives of the study:	15
Chapter Two	17
2. Literature Review:.....	17
2.1 Treatment Satisfaction and QoL:	17
2.2 Adherence and beliefs about medication:	18
2.3 Adherence, Treatment Satisfaction, and Glycemic control:	19
Chapter Three	22
3. Methodology:	22
3.1 Study Design:	22
3.2 Setting:.....	22
3.3 Study population:.....	22
3.4 Study sample:	22
3.5 Selection criteria:	23
3.6 Ethical approval:	23
3.7 Data collection:	23
3.8 Measures:	24
3.8.1 Beliefs about Medicines Questionnaire:	24
3.8.2 Medication adherence measure:	25
3.8.3 Treatment Satisfaction Measure:.....	26
3.8.4 Health-Related Quality of Life Measure:	27
3.9 Statistical analysis:	27
3.10 Null Hypothesis:.....	28
Chapter Four	29

4. Results:	29
4.1 Patients' characteristics:	29
Chapter Five.....	51
5. Discussion.	51
Chapter Six.....	57
6.Conclusions and Recommendations	57
6.1. CONCLUSION.	57
6.2 Recommendations.	58
References:.....	59
Appendixes:	66
الملخص	87

List of Tables:

Table 1: Socio –Demographic and clinical patients information	29
Table 2: Medications history and manner of prescribing anti-diabetic drugs.	32
Table 3: Adherent and non-adherent patients and correlation with treatment satisfaction.	40
Table 4: Patient’s Glycemic control correlation with treatment satisfaction domain.	42
Table 5: Correlation between adherence level and beliefs about medicine scores.	44
Table 6: Association between glycemic control and beliefs about medicine scores.	46
Table 7: EQ-VAS score correlation with treatment satisfaction.	50

List of Figures:

Figure 1: Classification of the study participants according to their level of adherence.	33
Figure 2: Patient's answers to 4 –questions in Morisky Scale.	34
Figure 3: Percent of patients according to HbA1Cc test.	35
Figure 4 : Percent of patients that agree with the necessity score questions	36
Figure 5 : Percent of patients that agree with the concern score questions	37
Figure 6 : Classification of patients in the basis of their beliefs about medicine.	38
Figure 7: Mean treatment satisfaction scores based on the patient's level of adherence.	39
Figure 8: Patient's Glycemic control correlation with treatment satisfaction domains	41
Figure 9: Adherent and non-adherent patients beliefs about medicine scores.	43
Figure 10: Glycemic control correlation with BMQ scores.	45
Figure 11: Classification of patient's response to EQ-5D modalities.	47
Figure 12: Distribution of patient's EQ-VAS cores according to their level of adherence.	48
Figure 13: Classification of TSQM response modalities for the EQ-5D	49